Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-12-10 11:38
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib 2019-11-20 11:41
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-11-07 11:02
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability 2019-09-30 18:29
CStone Pharmaceuticals Reports First Half 2019 Financial Results 2019-08-15 15:31
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST 2019-07-10 10:23
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib 2019-06-10 09:30
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint 2019-05-23 18:36
1